Search

Your search keyword '"Blanco‐Vaca, Francisco"' showing total 667 results
Start Over Author "Blanco‐Vaca, Francisco"
667 results on '"Blanco‐Vaca, Francisco"'

2. PCSK9 Antibodies Treatment Specifically Enhances the Macrophage-specific Reverse Cholesterol Transport Pathway in Heterozygous Familial Hypercholesterolemia

Author

Borràs, Carla, Canyelles, Marina, Girona, Josefa, Ibarretxe, Daiana, Santos, David, Revilla, Giovanna, Llorente-Cortes, Vicenta, Rotllan, Noemí, Kovanen, Petri T., Jauhiainen, Matti, Lee-Rueckert, Miriam, Masana, Luis, Arrieta, Francisco, Martínez-Botas, Javier, Gómez-Coronado, Diego, Ribalta, Josep, Tondo, Mireia, Blanco-Vaca, Francisco, and Escolà-Gil, Joan Carles

Published
2024
Full Text
View/download PDF

4. Consenso sobre lipoproteína (a) de la Sociedad Española de Arteriosclerosis. Revisión bibliográfica y recomendaciones para la práctica clínica

Author

Delgado-Lista, Javier, Mostaza, Jose M., Arrobas-Velilla, Teresa, Blanco-Vaca, Francisco, Masana, Luis, Pedro-Botet, Juan, Perez-Martinez, Pablo, Civeira, Fernando, Cuende-Melero, Jose I., Gomez-Barrado, Jose J., Lahoz, Carlos, Pintó, Xavier, Suarez-Tembra, Manuel, Lopez-Miranda, Jose, and Guijarro, Carlos

Published
2024
Full Text
View/download PDF

5. HDL and LDL: Potential New Players in Breast Cancer Development.

Author

Cedó, Lídia, Reddy, Srinivasa T, Mato, Eugènia, Blanco-Vaca, Francisco, and Escolà-Gil, Joan Carles

Subjects
27-hydroxycholesterol, Breast cancer, HDL, LDL, cholesterol, cholesterol-lowering therapies, Clinical Sciences
Abstract

Breast cancer is the most prevalent cancer and primary cause of cancer-related mortality in women. The identification of risk factors can improve prevention of cancer, and obesity and hypercholesterolemia represent potentially modifiable breast cancer risk factors. In the present work, we review the progress to date in research on the potential role of the main cholesterol transporters, low-density and high-density lipoproteins (LDL and HDL), on breast cancer development. Although some studies have failed to find associations between lipoproteins and breast cancer, some large clinical studies have demonstrated a direct association between LDL cholesterol levels and breast cancer risk and an inverse association between HDL cholesterol and breast cancer risk. Research in breast cancer cells and experimental mouse models of breast cancer have demonstrated an important role for cholesterol and its transporters in breast cancer development. Instead of cholesterol, the cholesterol metabolite 27-hydroxycholesterol induces the proliferation of estrogen receptor-positive breast cancer cells and facilitates metastasis. Oxidative modification of the lipoproteins and HDL glycation activate different inflammation-related pathways, thereby enhancing cell proliferation and migration and inhibiting apoptosis. Cholesterol-lowering drugs and apolipoprotein A-I mimetics have emerged as potential therapeutic agents to prevent the deleterious effects of high cholesterol in breast cancer.

Published
2019

7. The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone

Author

Delaby, Constance, Estellés, Teresa, Zhu, Nuole, Arranz, Javier, Barroeta, Isabel, Carmona-Iragui, María, Illán-Gala, Ignacio, Santos-Santos, Miguel Ángel, Altuna, Miren, Sala, Isabel, Sánchez-Saudinós, M. Belén, Videla, Laura, Valldeneu, Sílvia, Subirana, Andrea, Tondo, Mireia, Blanco-Vaca, Francisco, Lehmann, Sylvain, Belbin, Olivia, Blesa, Rafael, Fortea, Juan, Lleó, Alberto, and Alcolea, Daniel

Published
2022
Full Text
View/download PDF

9. Low-density lipoprotein receptor-related protein 1 deficiency in cardiomyocytes reduces susceptibility to insulin resistance and obesity

Author

Benitez-Amaro, Aleyda, Revuelta-López, Elena, Bornachea, Olga, Cedó, Lídia, Vea, Àngela, Herrero, Laura, Roglans, Nuria, Soler-Botija, Carolina, de Gonzalo-Calvo, David, Nasarre, Laura, Camino-López, Sandra, García, Eduardo, Mato, Eugenia, Blanco-Vaca, Francisco, Bayes-Genis, Antoni, Sebastian, David, Laguna, Joan Carles, Serra, Dolors, Zorzano, Antonio, Escola-Gil, Joan Carles, and Llorente-Cortes, Vicenta

Published
2020
Full Text
View/download PDF

10. ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer.

Author

Cedó, Lídia, García-León, Annabel, Baila-Rueda, Lucía, Santos, David, Grijalva, Victor, Martínez-Cignoni, Melanie Raquel, Carbó, José M, Metso, Jari, López-Vilaró, Laura, Zorzano, Antonio, Valledor, Annabel F, Cenarro, Ana, Jauhiainen, Matti, Lerma, Enrique, Fogelman, Alan M, Reddy, Srinivasa T, Escolà-Gil, Joan Carles, and Blanco-Vaca, Francisco

Subjects
Animals, Mice, Transgenic, Humans, Mice, Breast Neoplasms, Lipoproteins, LDL, Peptides, Apolipoprotein A-I, Antineoplastic Agents, Xenograft Model Antitumor Assays, Cell Proliferation, Cell Survival, Molecular Mimicry, Female, MCF-7 Cells, Lipoproteins, LDL, Transgenic
Abstract

Low levels of high-density lipoprotein cholesterol (HDLc) have been associated with breast cancer risk, but several epidemiologic studies have reported contradictory results with regard to the relationship between apolipoprotein (apo) A-I and breast cancer. We aimed to determine the effects of human apoA-I overexpression and administration of specific apoA-I mimetic peptide (D-4F) on tumour progression by using mammary tumour virus-polyoma middle T-antigen transgenic (PyMT) mice as a model of inherited breast cancer. Expression of human apoA-I in the mice did not affect tumour onset and growth in PyMT transgenic mice, despite an increase in the HDLc level. In contrast, D-4F treatment significantly increased tumour latency and inhibited the development of tumours. The effects of D-4F on tumour development were independent of 27-hydroxycholesterol. However, D-4F treatment reduced the plasma oxidized low-density lipoprotein (oxLDL) levels in mice and prevented oxLDL-mediated proliferative response in human breast adenocarcinoma MCF-7 cells. In conclusion, our study shows that D-4F, but not apoA-I-containing HDL, hinders tumour growth in mice with inherited breast cancer in association with a higher protection against LDL oxidative modification.

Published
2016

21. LDL Receptor Regulates the Reverse Transport of Macrophage-Derived Unesterified Cholesterol via Concerted Action of the HDL-LDL Axis: Insight From Mouse Models

Author

Cedó, Lídia, Metso, Jari, Santos, David, García-León, Annabel, Plana, Núria, Sabate-Soler, Sonia, Rotllan, Noemí, Rivas-Urbina, Andrea, Méndez-Lara, Karen A., Tondo, Mireia, Girona, Josefa, Julve, Josep, Pallarès, Victor, Benitez-Amaro, Aleyda, Llorente-Cortes, Vicenta, Pérez, Antonio, Gómez-Coronado, Diego, Ruotsalainen, Anna-Kaisa, Levonen, Anna-Liisa, Sanchez-Quesada, José Luis, Masana, Luís, Kovanen, Petri T., Jauhiainen, Matti, Lee-Rueckert, Miriam, Blanco-Vaca, Francisco, and Escolà-Gil, Joan Carles

Published
2020
Full Text
View/download PDF

23. HDL and Lifestyle Interventions

Author

Escolà-Gil, Joan Carles, Julve, Josep, Griffin, Bruce A., Freeman, Dilys, Blanco-Vaca, Francisco, Rosenthal, Walter, Editor-in-chief, Barrett, James E., Series editor, Flockerzi, Veit, Series editor, Frohman, Michael A., Series editor, Geppetti, Pierangelo, Series editor, Hofmann, Franz B., Series editor, Michel, Martin C., Series editor, Moore, Philip, Series editor, Page, Clive P., Series editor, Thorburn, Andrew M., Series editor, Wang, KeWei, Series editor, von Eckardstein, Arnold, editor, and Kardassis, Dimitris, editor

Published
2015
Full Text
View/download PDF

34. Impact of phenol-enriched virgin olive oils on serum metabonome and its relationship with cardiometabolic parameters

Author

Farràs, Marta, Swann, Jonathan R., Rowland, Ian, Rubió, Laura, Subirana, Isaac, Catalán, Úrsula, Motilva, María-José, Solá, Rosa, Covas, María Isabel, Blanco-Vaca, Francisco, Fitó, Montserrat, Mayneris-Perxachs, Jordi, Generalitat de Catalunya, Instituto de Salud Carlos III, and European Commission

Subjects
Cardiovascular diseases, Metabonomics, Functional olive oil, Phenolic compounds
Abstract

Phenol-rich foods consumption such as virgin olive oil (VOO) has been shown to have beneficial effects on cardiovascular diseases. The broader biochemical impact of VOO and phenolenriched OOs remains, however, unclear. A randomized, double-blind, cross-over, controlled trial was performed with thirty-three hypercholesterolemic individuals who ingested for 3-weeks (25 mL/day): (1) an OO enriched with its own olive oil phenolic compounds (PCs) (500 ppm; FOO); (2) an OO enriched with its own olive oil PCs (250 ppm) plus thyme PCs (250 ppm; FOOT); and (3) a VOO with low phenolic content (80 ppm). Serum lipid and glycemic profiles, serum 1H-NMR spectroscopybased metabolomics, endothelial function, blood pressure, and cardiovascular risk were measured. We combined OPLS-DA with machine learning modelling to identify metabolites discrimination of the treatment groups. Both phenol-enriched OO interventions decreased the levels of glutamine, creatinine, creatine, dimethylamine, and histidine in comparison to VOO one. In addition, FOOT decreased the plasma levels of glycine and DMSO2 compared to VOO, while FOO decreased the circulating alanine concentrations but increased the plasma levels of acetone and 3-HB compared to VOO. Based on these findings, phenol-enriched OOs were shown to result in a favorable shift in the circulating metabolic phenotype, inducing a reduction in metabolites associated with cardiometabolic diseases., We are grateful to the CERCA Program/Generalitat de Catalunya for institutional support. J.M.-P. acknowledges the support of the Instituto de Salud Carlos III (ISCIII) through project PI20/01090 co-funded by the European Union under the European Regional Development Fund (FEDER) ‘A way to make Europe’ and project CP18/00009 co-funded by the European Union under the European Social Fund (FSE) ‘Investing in your Future’.

Published
2022

35. Divergent Effects of Glycemic Control and Bariatric Surgery on Circulating Concentrations of TMAO in Newly Diagnosed T2D Patients and Morbidly Obese

Author

Canyelles, Marina, primary, Pérez, Antonio, additional, Junza, Alexandra, additional, Miñambres, Inka, additional, Yanes, Oscar, additional, Sardà, Helena, additional, Rotllan, Noemí, additional, Julve, Josep, additional, Sánchez-Quesada, José Luis, additional, Tondo, Mireia, additional, Escolà-Gil, Joan Carles, additional, and Blanco-Vaca, Francisco, additional

Published
2022
Full Text
View/download PDF

36. Impact of Phenol-Enriched Olive Oils on Serum Metabonome and Its Relationship with Cardiometabolic Parameters: A Randomized, Double-Blind, Cross-Over, Controlled Trial

Author

Farràs, Marta, primary, Swann, Jonathan Richard, additional, Rowland, Ian, additional, Rubió, Laura, additional, Subirana, Isaac, additional, Catalán, Úrsula, additional, Motilva, Maria José, additional, Solà, Rosa, additional, Covas, Maria Isabel, additional, Blanco-Vaca, Francisco, additional, Fitó, Montserrat, additional, and Mayneris-Perxachs, Jordi, additional

Published
2022
Full Text
View/download PDF

46. NAD+-Increasing Strategies to Improve Cardiometabolic Health?

Author

Blanco Vaca, Francisco, Rotllan, Noemi, Canyelles, Marina, Mauricio Puente, Dídac, Escola-Gil, Joan Carles, Julve, Josep, Universitat Autònoma de Barcelona, Blanco Vaca, Francisco, Rotllan, Noemi, Canyelles, Marina, Mauricio Puente, Dídac, Escola-Gil, Joan Carles, Julve, Josep, and Universitat Autònoma de Barcelona

Abstract

Depleted nicotinamide adenine dinucleotide (NAD+) is a common hallmark of metabolic disorders. Therefore, NAD+-increasing strategies have evolved as a potential therapeutic venue to combat cardiometabolic diseases. Several forms of vitamin B3, i.e., nicotinamide and nicotinamide mononucleotide, and especially nicotinamide riboside, have attracted most interest as potentially safe and efficacious candidates for NAD+ restoration. Herein, we dissected the characteristics of the latest clinical trials testing the therapeutic potential of different vitamin B3 molecules to improve cardiometabolic health, with a special focus on randomized, placebo-controlled clinical trials performed in the context of obesity or other pathologies, mainly linked to cardiovascular system and skeletal muscle functionality. The favorable outcomes via NAD+-increasing strategies found in the different studies were quite heterogeneous. NAD+-increasing interventions improved capacity to exercise, decreased blood pressure, increased the anti-inflammatory profile and insulin-stimulated glucose disposal, and reduced the fat-free mass. Except for the decreased blood pressure, the significant results did not include many hard clinical end points, such as decreases in weight, BMI, fasting glucose, or HbA1c percentage. However, the analyzed trials were short-term interventions. Overall, the accumulated clinical data can be interpreted as moderately promising. Additional and long-term studies will be needed to directly compare the doses and duration of treatments among different vitamin B3 regimes, as well as to define the type of patients, if any, that could benefit from these treatments. In this context, a major point of advancement in delineating future clinical trials would be to identify subjects with a recognized NAD+ deficiency using novel, appropriate biomarkers. Also, confirmation of gender-specific effect of NAD+-increasing treatments would be needed.

Published
2022

47. Impact of phenol-enriched virgin olive oils on serum metabonome and its relationship with cardiometabolic parameters

Author

Generalitat de Catalunya, Instituto de Salud Carlos III, European Commission, Farràs, Marta, Swann, Jonathan R., Rowland, Ian, Rubió, Laura, Subirana, Isaac, Catalán, Úrsula, Motilva, María-José, Solá, Rosa, Covas, María Isabel, Blanco-Vaca, Francisco, Fitó, Montserrat, Mayneris-Perxachs, Jordi, Generalitat de Catalunya, Instituto de Salud Carlos III, European Commission, Farràs, Marta, Swann, Jonathan R., Rowland, Ian, Rubió, Laura, Subirana, Isaac, Catalán, Úrsula, Motilva, María-José, Solá, Rosa, Covas, María Isabel, Blanco-Vaca, Francisco, Fitó, Montserrat, and Mayneris-Perxachs, Jordi

Abstract

Phenol-rich foods consumption such as virgin olive oil (VOO) has been shown to have beneficial effects on cardiovascular diseases. The broader biochemical impact of VOO and phenolenriched OOs remains, however, unclear. A randomized, double-blind, cross-over, controlled trial was performed with thirty-three hypercholesterolemic individuals who ingested for 3-weeks (25 mL/day): (1) an OO enriched with its own olive oil phenolic compounds (PCs) (500 ppm; FOO); (2) an OO enriched with its own olive oil PCs (250 ppm) plus thyme PCs (250 ppm; FOOT); and (3) a VOO with low phenolic content (80 ppm). Serum lipid and glycemic profiles, serum 1H-NMR spectroscopybased metabolomics, endothelial function, blood pressure, and cardiovascular risk were measured. We combined OPLS-DA with machine learning modelling to identify metabolites discrimination of the treatment groups. Both phenol-enriched OO interventions decreased the levels of glutamine, creatinine, creatine, dimethylamine, and histidine in comparison to VOO one. In addition, FOOT decreased the plasma levels of glycine and DMSO2 compared to VOO, while FOO decreased the circulating alanine concentrations but increased the plasma levels of acetone and 3-HB compared to VOO. Based on these findings, phenol-enriched OOs were shown to result in a favorable shift in the circulating metabolic phenotype, inducing a reduction in metabolites associated with cardiometabolic diseases.

Published
2022

48. Impact of Phenol-Enriched Olive Oils on Serum Metabonome and Its Relationship with Cardiometabolic Parameters: A Randomized, Double-Blind, Cross-Over, Controlled Trial

Author

Universitat Rovira i Virgili, Farras, Marta; Swann, Jonathan Richard; Rowland, Ian; Rubio, Laura; Subirana, Isaac; Catalan, Ursula; Jose Motilva, Maria; Sola, Rosa; Covas, Maria Isabel; Blanco-Vaca, Francisco; Fito, Montserrat; Mayneris-Perxachs, Jordi, Universitat Rovira i Virgili, and Farras, Marta; Swann, Jonathan Richard; Rowland, Ian; Rubio, Laura; Subirana, Isaac; Catalan, Ursula; Jose Motilva, Maria; Sola, Rosa; Covas, Maria Isabel; Blanco-Vaca, Francisco; Fito, Montserrat; Mayneris-Perxachs, Jordi

Abstract

Phenol-rich foods consumption such as virgin olive oil (VOO) has been shown to have beneficial effects on cardiovascular diseases. The broader biochemical impact of VOO and phenol-enriched OOs remains, however, unclear. A randomized, double-blind, cross-over, controlled trial was performed with thirty-three hypercholesterolemic individuals who ingested for 3-weeks (25 mL/day): (1) an OO enriched with its own olive oil phenolic compounds (PCs) (500 ppm; FOO); (2) an OO enriched with its own olive oil PCs (250 ppm) plus thyme PCs (250 ppm; FOOT); and (3) a VOO with low phenolic content (80 ppm). Serum lipid and glycemic profiles, serum H-1-NMR spectroscopy-based metabolomics, endothelial function, blood pressure, and cardiovascular risk were measured. We combined OPLS-DA with machine learning modelling to identify metabolites discrimination of the treatment groups. Both phenol-enriched OO interventions decreased the levels of glutamine, creatinine, creatine, dimethylamine, and histidine in comparison to VOO one. In addition, FOOT decreased the plasma levels of glycine and DMSO2 compared to VOO, while FOO decreased the circulating alanine concentrations but increased the plasma levels of acetone and 3-HB compared to VOO. Based on these findings, phenol-enriched OOs were shown to result in a favorable shift in the circulating metabolic phenotype, inducing a reduction in metabolites associated with cardiometabolic diseases.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results